AB0562 POTENTIAL BIOMARKERS OF PERSONALIZED TREATMENT BASED ON CARDIOVASCULAR-RELATED COMORBIDITIES IN PSORIATIC ARTHRITIS

Background: Psoriatic Arthritis (PsA) displays increased traditional cardiovascular (CV) risk factors, such as insulin resistance (IR), metabolic syndrome or obesity. Thus, it is an urgent need to treat and manage these cardiometabolic comorbidities associated. Some evidence points out that methotrexate could improve CV due its anti-inflammatory properties, however the effect of PDE4 inhibitor treatment on have not been elucidated yet. Objectives: 1) To evaluate conventional therapy in PsA patients with high prevalence comorbidities. 2) identify a molecular patient profile susceptible being benefit from each regarding disease activity risk. Methods: Thirty biological-naïve were treated (Apremilast), Methotrexate combined (Apremilast Methotrexate) following clinical routine practice for 6 months. A cohort 30 age sex-matched healthy donors (HDs) was included. Plasma peripheral blood mononuclear cells (PBMCs) isolated HDs. Different parameters related analyzed, including: atherogenic index, ratio apolipoprotein B (apo B)/apolipoprotein A), syndrome, obesity, arterial hypertension, SCORE. Clinical analytical collected: lipid (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, apo B), glucose insulin, body surface area (BSA) affected by psoriasis, number tender swollen joints, DAPSA, C-reactive protein erythrocyte sedimentation rate. panel 92 proteins involved (cardiovascular II, Olink) adipocytokine measured plasma PBMCs. Hard cluster analysis carried order two distinctive phenotypes depending response reduction Results: Among CV-related proteins, higher levels molecules, CD163 FABP4 observed compared HDs, strongly associated elevated rates factors B/A risks, IR, hypertension smoking. we profiles according molecules: 1 defined 20 low 2 10 CVD Regarding 2, those Apremilast had significant drop total B, IR state mass index. In addition, both reduced disease. However, monotherapy did show beneficial displaying CD163, FABP4, cholesterol no changes after treatment. regard 1, three strategies Even comorbidities, index months therapy. Apremilast. Conclusion: 1- be considered potential biomarkers efficacy 2- might target alterations modulating profile, decreasing surrogate molecules. 3- should Funded ISCIII (PI17/01316 RIER RD16/0012/0015) co-funded FEDER. Disclosure Interests: None declared.